Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the ISGIO 2025 meeting focused on updates in the management of hepatobiliary cancers. This included a presentation on the role of liver transplant in the management of cholangiocarcinoma and another on the use of HER2-directed therapies in advanced biliary tract cancers. The latter portion of the session was dedicated to advances in immunotherapy for intermediate- and advanced-stage hepatocellular cancer, framed by presentation and discussion of a patient case.
Registration is
also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft
Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing results to individualize treatment selection for patients with GI cancers
- Evaluate the latest efficacy and safety data for newly approved agents, novel combinations, and novel agents to consider their potential impact on evolving treatment paradigms in GI cancers
Natasha Bahri, MD, MSc
Y3 Chief Fellow
Department of Medical Oncology and Hematology
City of Hope
Duarte, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Daiichi Sankyo, Seagen; Grant/Research Funding (to institution): AbbVie, Black Diamond, Boehringer Ingelheim, Daiichi Sankyo, lmmunoGen; Royalty or Patent Benefits: Takeda
Ashton A. Connor, MD, PhD
Assistant Professor of Surgery, Academic Institute
Member, Research Institute, Academic Institute
Department of Surgery
Houston Methodist Hospital
Assistant Professor of Surgery
Weill Cornell Medical College
Houston, TX
Disclosures: Ashton A. Connor, MD, PhD, has no relevant financial relationships with ineligible companies.
James J. Harding, MD
Associate Attending Physician
Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cogent, Eisai, Elevar, Exelixis, Jazz, Merck, RayzeBio, Servier; Grant/Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Jazz, Kinnate, LOXO@Lilly, Tvardi, Zymeworks
Daneng Li, MD
Associate Professor
Department of Medical Oncology and Therapeutics Research
Cancer and Aging Research Group
Co-Director, Neuroendocrine Tumor Program
City of Hope
Duarte, CA
Disclosures: Grant/Research Funding (to institution): AstraZeneca; Consultant: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Coherus, Eisai, Elevar, Exelixis, Jazz, Merck, Merus, Roche/Genentech, Sumitomo, TransThera, TriSalus
Shubham Pant, MD, MBBS
Professor
Department of Investigational Cancer Therapeutics
Department of Gastrointestinal Medical Oncology
Director, Clinical Research
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGbio, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, Merck, Nihon Medi-Physics Co Ltd, Novartis, Pfizer, Revolution Medicines, Theriva Biosciences, US WorldMeds, Zymeworks; Grant/Research Funding: Amal Therapeutics, Arcus, Astellas, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Elicio, Framewave, Immuneering, Immunomet Therapeutics, Ipsen, Janssen, Jazz Therapeutics, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution Medicines, Zymeworks; Ownership interests in privately held companies: Telperian
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
